Related Experiment Video
Updated: Jul 4, 2026
09:44
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
Metastatic Crohn's disease: a review
I Palamaras1, J El-Jabbour, N Pietropaolo
1Barnet & Chase Farm NHS Trust, Dermatology, London, UK. drioulios@hotmail.com
Summary
Metastatic Crohn's disease (MCD), a rare skin condition, presents with granulomas away from the gut. Diagnosis and treatment are challenging, highlighting the need for increased awareness and research.
Area of Science:
- Dermatology
- Gastroenterology
- Immunology
Background:
- Metastatic Crohn's disease (MCD) is the least common dermatologic manifestation of Crohn's disease (CD).
- It involves non-caseating granulomas in the skin, distinct from the gastrointestinal tract.
- MCD presentation and timing relative to CD diagnosis differ between adults and children.
Purpose of the Study:
- To review the key characteristics of Metastatic Crohn's disease.
- To enhance awareness and understanding of this rare condition.
- To guide improved diagnosis and management strategies for CD patients.
Main Methods:
- Literature review of existing studies on Metastatic Crohn's disease.
- Analysis of clinical presentations, demographics, and treatment outcomes.
- Synthesis of information to provide a comprehensive overview.
Main Results:
- MCD typically manifests as nodules, plaques, or ulcers in adults, and genital swelling in children.
- In children, MCD often co-occurs with CD diagnosis and perianal disease.
- Treatment options are varied and often yield unsatisfactory results, with a lack of randomized controlled trials.
Conclusions:
- Metastatic Crohn's disease is a diagnostic challenge, often mimicking other conditions.
- Increased clinical awareness is crucial for timely diagnosis and effective management.
- Further research, including randomized controlled trials, is needed to optimize treatment strategies.
More Related Videos
Related Concept Videos
01:30Inflammatory Bowel Disease II: Crohn's Disease
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:17Chronic Bowel Disorders: Introduction
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...